ECM
FLGT icon

ExodusPoint Capital Management’s Fulgent Genetics FLGT Stock Holding History

ExodusPoint Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,000
Closed -$1.04M – 2257
2020
Q4 		$1.04M Sell
20,000
-28,300
-59% -$1.18M 0.01% 838
2020
Q3 		$1.94M Buy
+48,300
New +$1.51M 0.04% 419

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ExodusPoint Capital Management's FLGT Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Fulgent Genetics (FLGT) in Q1 2026, closing a stake of 13,975 shares — an estimated $367K sold.

ExodusPoint Capital Management first reported a position in FLGT in Q4 2019 and held it in 15 quarters. The position peaked at $2.62M in Q1 2023. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • ExodusPoint Capital Management reported no remaining Fulgent Genetics position as of Q1 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 13,975 Fulgent Genetics shares in Q1 2026, an estimated $367K.
  • ExodusPoint Capital Management first reported a position in Fulgent Genetics in Q4 2019 and held it in 15 quarters.
  • ExodusPoint Capital Management's Fulgent Genetics position peaked at $2.62M in Q1 2023.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.